Sugi Predict

Sugi Predict / Compounds / SCHEMBL1192976

SCHEMBL1192976

SCHEMBL1192976

O=C(Nc1c(Br)cc(F)cc1Br)N(S)C(=O)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ NPC1 O15118 3/20 0.39
▸ RAB9A P51151 3/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ PKM P14618 1/20 0.39
▸ GAA P10253 1/20 0.38
▸ PLK1 P53350 1/20 0.37
▸ HPGD P15428 1/20 0.36
▸ KCNK3 O14649 2/20 0.35
▸ KCNK9 Q9NPC2 1/20 0.35
▸ RECQL P46063 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ EGFR P00533 1/20 0.34
▸ ERBB2 P04626 1/20 0.34
▸ HDAC1 Q13547 2/20 0.34
▸ HDAC8 Q9BY41 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3663619 0.78 RAB9A (0.42) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL220680 0.75 MEN1 (0.41) MEN1KMT2AALDH1A1RAB9ASMN1; SMN2
SCHEMBL3662242 0.75 HDAC1 (0.46) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL14859165 0.74 ALDH1A1 (0.51) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL222250 0.73 MEN1 (0.36) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL10608197 0.72 RAB9A (0.36) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL1192974 0.70 PLK1 (0.70) ALDH1A1NPC1MAPTGAAPLK1
SCHEMBL220188 0.70 MEN1 (0.37) MEN1KMT2AALDH1A1RAB9ASMN1; SMN2
SCHEMBL220071 0.70 SMN1; SMN2 (0.37) MEN1KMT2AL3MBTL1ALDH1A1NPC1
SCHEMBL5713541 0.70 THRB (0.51) MEN1KMT2ANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11618744-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2023-04-04 — — US disclosed
US-20210078978-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-03-18 — — US disclosed
US-10851083-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2020-12-01 — — US disclosed
US-20180215732-A9 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-08-02 — — US disclosed
US-20180022733-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-01-25 — — US disclosed
US-20160168127-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2016-06-16 — — US disclosed
US-9073923-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-07-07 — — US disclosed
EP-2294066-B9 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2015-03-11 — — EP disclosed
US-8865713-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-10-21 — — US disclosed
US-20140256722-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-11 — — US disclosed
EP-2294066-B1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-08-13 — — EP disclosed
US-8759345-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 — — US disclosed
US-20140005193-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (US) 2014-01-02 — — US disclosed
EP-2294066-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2011-03-16 — — EP disclosed
US-20110046132-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2011-02-24 — — US disclosed
WO-2009134750-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-11-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11618744-B2 Benzoimidazoles as prolyl hydroxylase inhibitors P4HA1, PAH, EGLN3 MEN1 4176/4885KMT2A 1663/4885L3MBTL1 3088/4885
US-20110046132-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MEN1 4038/4885KMT2A 1901/4885L3MBTL1 3171/4885
US-20180022733-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MEN1 4176/4885KMT2A 1663/4885L3MBTL1 3088/4885
US-20140005193-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MEN1 4176/4885KMT2A 1663/4885L3MBTL1 3088/4885
US-10851083-B2 Benzoimidazoles as prolyl hydroxylase inhibitors P4HA1, PAH, EGLN3 MEN1 4176/4885KMT2A 1663/4885L3MBTL1 3088/4885
US-20180215732-A9 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MEN1 4176/4885KMT2A 1663/4885L3MBTL1 3088/4885
US-20140256722-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MEN1 4176/4885KMT2A 1663/4885L3MBTL1 3088/4885
US-20210078978-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MEN1 4176/4885KMT2A 1663/4885L3MBTL1 3088/4885
US-20160168127-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MEN1 4176/4885KMT2A 1663/4885L3MBTL1 3088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.